Physician-dispensed sales increased $0.4 million, to $28.2 million during the three months ended June 30, 2011, as compared to $27.8 million during the three months ended June 30, 2010. This prolong was primarily due to increases of $0.6 million in each of the Nu-Derm and Other categories. The growth in our Nu-Derm sales was primarily due to the launch of Nu-Derm Sun Shield SPF 50 in January 2011, which contributed $0.8 million and the lump in the Other category was primarily attributable to the launch of Blue Peel RADIANCE in January 2011, which contributed $0.3 million. These increases were up to a given offset by: (i) a decrease in the Therapeutic category of $0.4 million, primarily due to a decline in sales of our CLENZIderm consequence line; (ii) a decrease in Vitamin C sales of $0.3 million; and (iii) a decrease in Elasticity sales of $0.1 million. Licensing fees decreased by $0.4 million due particularly to the return of new products launched by our Japanese partner, Rohto, during the three months ended March 31, 2011. We currently cannot assess the on-successful impact the March 2011 Japanese earthquake and tsunami may have on our future licensing revenues.
